Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Sexual Health Reports
Erschienen in: Current Sexual Health Reports 4/2017

22.11.2017 | Medical Comorbidities (M Miner, S Parish and A Goldstein, Section Editors)

Testosterone and Physical Function

verfasst von: Swaytha Yalamanchi, Rita R. Kalyani, Brian Buta, Adrian Dobs

Erschienen in: Current Sexual Health Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to provide an overview of recent data on the relationship of testosterone with physical function.

Recent Findings

The safety of testosterone treatment in older men who do not have hypogonadism has increasingly been questioned. In recent years, multiple studies have been performed to better understand the relationship between testosterone and physical function.

Summary

Overall, the relationship between testosterone and physical function is unclear. Endogenous and exogenous testosterones are associated with favorable changes in body composition and, to a lesser extent, muscle strength. However, the relationship between testosterone and physical function is less clear in healthy older men. Exogenous testosterone is associated with favorable changes in body composition and strength, but further data are needed to understand if treatment is associated with functional improvements and ultimately decreased disability and morbidity.
Literatur
1.
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.PubMedCrossRef
2.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.PubMedCrossRef
3.
Lapauw B, Goemaere S, Zmierczak H, Van Pottelbergh I, Mahmoud A, Taes Y, et al. The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes. Eur J Endocrinol. 2008;159(4):459–68.PubMedCrossRef
4.
Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–98.PubMedCrossRef
5.
Morley JE, Kaiser FE, Perry HM, Patrick P, Morley PM, Stauber PM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46(4):410–3.PubMedCrossRef
6.
Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73(5):1016–25.PubMedCrossRef
7.
Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91(4):1336–44.PubMedCrossRef
8.
Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Jamrozik K, et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007;156(5):585–94.PubMedCrossRef
9.
Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, et al. The influence of aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol. 1992;135(7):783–91.PubMedCrossRef
10.
Svartberg J, Midtby M, Bonaa KH, Sundsfjord J, Joakimsen RM, Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol. 2003;149(2):145–52.PubMedCrossRef
11.
Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab. 1980;51(1):35–40.PubMedCrossRef
12.
Nieschlag E, Lammers U, Freischem CW, Langer K, Wickings EJ. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab. 1982;55(4):676–81.PubMedCrossRef
13.
Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997;146(8):609–17.PubMedCrossRef
14.
Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920–6.PubMedCrossRef
15.
Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol. 1999;141(3):257–66.PubMedCrossRef
16.
Veldhuis JD, Urban RJ, Dufau ML. Differential responses of biologically active luteinizing hormone secretion in older versus young men to interruption of androgen negative feedback. J Clin Endocrinol Metab. 1994;79(6):1763–70.PubMed
17.
Veldhuis JD, Zwart A, Mulligan T, Iranmanesh A. Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. J Clin Endocrinol Metab. 2001;86(2):529–35.PubMed
18.
Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. Rev Urol. 2003;5(Suppl 1):S10.
19.
Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab. 2007;92(9):3599–603.PubMedCrossRef
20.
Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994;79(4):1086–90.PubMed
21.
O'Connell MD, Ravindrarajah R, Tajar A, Wu FC. Low testosterone in ageing men: a modifiable risk factor for frailty? Trends Endocrinol Metab. 2011;22(12):491–8.PubMedCrossRef
22.
Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol. 2006;65(1):125–31.CrossRef
23.
Mohr BA, Bhasin S, Link CL, O'Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol. 2006;155(3):443–52.PubMedCrossRef
24.
Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92(2):549–55.PubMedCrossRef
25.
Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737–45.PubMedCrossRef
26.
Crespo CJ, Keteyian SJ, Heath GW, Sempos CT. Leisure-time physical activity among US adults. Results from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 1996;156(1):93–8.PubMedCrossRef
27.
Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Investig. 1999;22(5 Suppl):110–6.
28.
Lindle RS, Metter EJ, Lynch NA, Fleg JL, Fozard JL, Tobin J, et al. Age and gender comparisons of muscle strength in 654 women and men aged 20–93 yr. J Appl Physiol 1997;83(5):1581–7.
29.
Candow DG, Chilibeck PD. Differences in size, strength, and power of upper and lower body muscle groups in young and older men. J Gerontol A Biol Sci Med Sci. 2005;60(2):148–56.PubMedCrossRef
30.
Fleg JL, Morrell CH, Bos AG, Brant LJ, Talbot LA, Wright JG, et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation. 2005;112(5):674–82.PubMedCrossRef
31.
O'Connell MD, Wu FC. Androgen effects on skeletal muscle: implications for the development and management of frailty. Asian J Androl. 2014;16(2):203–12.PubMedPubMedCentralCrossRef
32.
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.PubMedCrossRef
33.
Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):889–96.PubMedCrossRef
34.
Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55(5):769–74.PubMedCrossRef
35.
Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51(11):1602–9.PubMedCrossRef
36.
Bergman H, Ferrucci L, Guralnik J, Hogan DB, Hummel S, Karunananthan S, et al. Frailty: an emerging research and clinical paradigm—issues and controversies. J Gerontol A Biol Sci Med Sci. 2007;62(7):731–7.PubMedPubMedCentralCrossRef
37.
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59(3):255–63.PubMedCrossRef
38.
Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54(6):991–1001.PubMedCrossRef
39.
Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260.PubMedPubMedCentralCrossRef
40.
Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009;90(6):1579–85.PubMedPubMedCentralCrossRef
41.
Narici MV, Maffulli N, Maganaris CN. Ageing of human muscles and tendons. Disabil Rehabil. 2008;30(20–22):1548–54.PubMedCrossRef
42.
Koster A, Visser M, Simonsick EM, Yu B, Allison DB, Newman AB, et al. Association between fitness and changes in body composition and muscle strength. J Am Geriatr Soc. 2010;58(2):219–26.PubMedPubMedCentralCrossRef
43.
Koster A, Ding J, Stenholm S, Caserotti P, Houston DK, Nicklas BJ, et al. Does the amount of fat mass predict age-related loss of lean mass, muscle strength, and muscle quality in older adults? J Gerontol A Biol Sci Med Sci. 2011;66(8):888–95.PubMedCrossRef
44.
Russ DW, Gregg-Cornell K, Conaway MJ, Clark BC. Evolving concepts on the age-related changes in “muscle quality”. J Cachexia Sarcopenia Muscle. 2012;3(2):95–109.PubMedPubMedCentralCrossRef
45.
Bhasin S, Taylor WE, Singh R, Artaza J, Sinha-Hikim I, Jasuja R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci. 2003;58(12):1103.CrossRef
46.
Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):154.CrossRef
47.
Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 2006;91(8):3024–33.PubMedCrossRef
48.
Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003;285(1):197.CrossRef
49.
Braga M, Bhasin S, Jasuja R, Pervin S, Singh R. Testosterone inhibits transforming growth factor-beta signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action. Mol Cell Endocrinol. 2012;350(1):39–52.PubMedCrossRef
50.
Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414–24.PubMedCrossRef
51.
Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab. 2003;88(1):358–62.PubMedCrossRef
52.
Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab. 1999;84(8):2705–11.PubMed
53.
Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Phys. 1995;269(5 Pt 1):820.
54.
Araujo AB, Travison TG, Bhasin S, Esche GR, Williams RE, Clark RV, et al. Association between testosterone and estradiol and age-related decline in physical function in a diverse sample of men. J Am Geriatr Soc. 2008;56(11):2000–8.PubMedPubMedCentralCrossRef
55.
Chin KY, Soelaiman IN, Naina Mohamed I, Shahar S, Teng NI, Suhana Mohd Ramli E, et al. Testosterone is associated with age-related changes in bone health status, muscle strength and body composition in men. Aging Male. 2012;15(4):240–5.PubMedCrossRef
56.
Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57(12):772.CrossRef
57.
Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr. 2004;80(2):496–503.PubMed
58.
van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85(9):3276–82.PubMed
59.
Folland JP, Mc Cauley TM, Phypers C, Hanson B, Mastana SS. The relationship of testosterone and AR CAG repeat genotype with knee extensor muscle function of young and older men. Exp Gerontol. 2012 June 01;47(6):437–43.PubMedCrossRef
60.
• Mouser JG, Loprinzi PD, Loenneke JP. The association between physiologic testosterone levels, lean mass, and fat mass in a nationally representative sample of men in the United States. Steroids. 2016;115:62–6. Using data from 1999–2000 NHANES, the authors demonstrated that higher endogenous testosterone levels were associated with favorable lean and fat masses. PubMedCrossRef
61.
• Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100(3):1146–55. Cross-sectional study of baseline sex hormones in the Testosterone Trials that did not demonstrate an association of endogenous free or total testosterone with physical function in symptomatic older men with total testosterone < 275 ng/dl. PubMedCrossRef
62.
• Vandenput L, Mellstrom D, Laughlin GA, Cawthon PM, Cauley JA, Hoffman AR, et al. Low testosterone, but not estradiol, is associated with incident falls in older men: the International MrOS Study. J Bone Miner Res. 2017;32(6):1174–81. Utilizing data from the Osteoporotic Fractures in Men Study, the authors demonstrated an association with low endogenous total and bioavailable testosterone levels with increased falls in older men. PubMedCrossRef
63.
Auyeung TW, Lee JS, Kwok T, Leung J, Ohlsson C, Vandenput L, et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol. 2011;164(5):811–7.PubMedCrossRef
64.
Schaap LA, Pluijm SM, Deeg DJ, Penninx BW, Nicklas BJ, Lips P, et al. Low testosterone levels and decline in physical performance and muscle strength in older men: findings from two prospective cohort studies. Clin Endocrinol. 2008;68(1):42–50.CrossRef
65.
Krasnoff JB, Basaria S, Pencina MJ, Jasuja GK, Vasan RS, Ulloor J, et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab. 2010;95(6):2790–9.PubMedPubMedCentralCrossRef
66.
Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166(19):2124–31.PubMedCrossRef
67.
LeBlanc ES, Wang PY, Lee CG, Barrett-Connor E, Cauley JA, Hoffman AR, et al. Higher testosterone levels are associated with less loss of lean body mass in older men. J Clin Endocrinol Metab. 2011;96(12):3855–63.PubMedPubMedCentralCrossRef
68.
Perry HM, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49(8):1085–91.PubMedCrossRef
69.
Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, et al. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol. 2005;63(2):152–60.CrossRef
70.
O'Donnell AB, Travison TG, Harris SS, Tenover JL, McKinlay JB. Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2006;91(2):425–31.PubMedCrossRef
71.
Aksglaede L, Molgaard C, Skakkebaek NE, Juul A. Normal bone mineral content but unfavourable muscle/fat ratio in Klinefelter syndrome. Arch Dis Child. 2008;93(1):30–4.PubMedCrossRef
72.
Bojesen A, Birkebaek N, Kristensen K, Heickendorff L, Mosekilde L, Christiansen JS, et al. Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int. 2011;22(5):1441–50.PubMedCrossRef
73.
Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, et al. The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29(7):1591–8.PubMedCrossRef
74.
75.
Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36.PubMedCrossRef
76.
Wu IC, Lin XZ, Liu PF, Tsai WL, Shiesh SC. Low serum testosterone and frailty in older men and women. Maturitas. 2010;67(4):348–52.PubMedCrossRef
77.
Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab. 2010;95(7):3165–72.PubMedCrossRef
78.
Mohr BA, Bhasin S, Kupelian V, Araujo AB, O'Donnell AB, McKinlay JB. Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc. 2007;55(4):548–55.PubMedCrossRef
79.
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678–88.PubMedCrossRef
80.
Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282(3):601.CrossRef
81.
Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288(18):2282–92.PubMedCrossRef
82.
Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52.PubMedCrossRef
83.
Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):266.CrossRef
84.
Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43.PubMedPubMedCentralCrossRef
85.
Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647–59.PubMedCrossRef
86.
Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–10.PubMedCrossRef
87.
Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009;94(6):1991–2001.PubMedPubMedCentralCrossRef
88.
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647–53.PubMed
89.
Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.PubMedCrossRef
90.
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75(4):1092–8.PubMed
91.
Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66(10):1090–9.PubMedCrossRef
92.
Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58(7):618–25.PubMedCrossRef
93.
Frederiksen L, Hojlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr). 2012;34(1):145–56.CrossRef
94.
Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82(2):407–13.PubMed
95.
Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.PubMedCrossRef
96.
Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999;22(4):261–5.PubMedCrossRef
97.
Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. Eur J Endocrinol. 2012;166(3):469–76.PubMedCrossRef
98.
Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86(9):4078–88.PubMedCrossRef
99.
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63(3):280–93.CrossRef
100.
Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV. Androgen treatment and muscle strength in elderly men: a meta-analysis. J Am Geriatr Soc. 2006;54(11):1666–73.PubMedPubMedCentralCrossRef
101.
Brenowitz WD, Hubbard RA, Crane PK, Gray SL, Zaslavsky O, Larson EB. Longitudinal associations between self-rated health and performance-based physical function in a population-based cohort of older adults. PLoS One. 2014;9(11):e111761.PubMedPubMedCentralCrossRef
102.
•• Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24. Data from The Physical Function Trial within the Testosterone Trials, a randomized, placebo-controlled trial including 790 men ≥ 65 years of age with total testosterone ≤ 275 ng/dl, did not show evidence of improvements in physical function (6-min walking distance) with testosterone gel. PubMedPubMedCentralCrossRef
103.
Storer TW, Basaria S, Traustadottir T, Harman SM, Pencina K, Li Z, et al. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocrinol Metab. 2017;102(2):583–93.PubMed
104.
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):1172.
105.
• Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88(4):1478–85. Double-blind, placebo-controlled trial in which healthy men ≥ 60 years old with total testosterone levels of 100–400 ng/dl or free testosterone levels < 50 pg/ml were treated with 7.5g of 1% testosterone gel or placebo for three years. The authors demonstrated that testosterone treatment was associated with greater improvements in stair-climbing power, muscle mass, and power. PubMedCrossRef
106.
Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008;56(11):1991–9.PubMedPubMedCentralCrossRef
107.
Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes Endocrinol. 2016;4(11):943–56.PubMedCrossRef
108.
Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.PubMedPubMedCentralCrossRef
109.
Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.PubMedPubMedCentralCrossRef
110.
Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and “age-related hypogonadism”—FDA concerns. N Engl J Med. 2015;373(8):689–91.PubMedCrossRef
111.
Coetsee C, Terblanche E. The time course of changes induced by resistance training and detraining on muscular and physical function in older adults. Eur Rev Aging Phys Act. 2015;12:8. eCollection 2015 CrossRef
112.
Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;(3):CD002759. doi(3):CD002759.
113.
Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab. 2013;98(5):1891–900.PubMedPubMedCentralCrossRef
114.
Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One. 2011;6(12):e28512.PubMedPubMedCentralCrossRef
115.
Sunchatawirul K, Tantiwongse K, Chathaisong P, Thongyen S, Chumpathat N, Manosuthi W. Hypogonadism among HIV-infected men in Thailand. Int J STD AIDS. 2012;23(12):876–81.PubMedCrossRef
116.
Blick G. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Postgrad Med. 2013;125(2):30–9.PubMedCrossRef
117.
Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015;60(3):453–62.PubMedCrossRef
118.
Rochira V, Guaraldi G. Hypogonadism in the HIV-infected man. Endocrinol Metab Clin N Am. 2014;43(3):709–30.CrossRef
119.
Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2(11):692–9.PubMedCrossRef
120.
Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998;83(9):3155–62.PubMed
121.
Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000;283(6):763–70.PubMedPubMedCentralCrossRef
122.
Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133(5):348–55.PubMedCrossRef
123.
Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85(1):60–5.PubMed
124.
Knapp PE, Storer TW, Herbst KL, Singh AB, Dzekov C, Dzekov J, et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab. 2008;294(6):1135.CrossRef
Metadaten
Titel
Testosterone and Physical Function
verfasst von
Swaytha Yalamanchi
Rita R. Kalyani
Brian Buta
Adrian Dobs
Publikationsdatum
22.11.2017
Verlag
Springer US
Erschienen in
Current Sexual Health Reports / Ausgabe 4/2017
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-017-0136-z

Weitere Artikel der Ausgabe 4/2017

Current Sexual Health Reports 4/2017 Zur Ausgabe

Medical Comorbidities (M Miner, S Parish and A Goldstein, Section Editors)

Testosterone and Cardiovascular Diseases: Causes or Consequences: The Lesson from the Last 5 Years

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

Sexual Transmission of Cyst-Forming Coccidian Parasites with Complex Life Cycles

Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Persistent Genital Arousal Disorder: Current Conceptualizations and Etiologic Mechanisms

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

Preclinical Models for Assessment of Antidepressant Abuse Potential

Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Brain Imaging of Human Sexual Response: Recent Developments and Future Directions

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

The Role of Ovarian Hormones and the Medial Amygdala in Sexual Motivation

Neu im Fachgebiet Urologie

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

D-Mannose ohne Nutzen in der Prävention von HWI-Rezidiven

02.05.2024 Harnwegsinfektionen in der Urologie Nachrichten

D-Mannose, eine Hoffnungsträgerin in der Rezidivprophylaxe von Harnwegsinfektionen, hat in einer Studie nicht mehr bewirken können als ein Placebo. Die Empfehlung zur Einnahme entfalle damit, so die Autoren.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise